Home/Grove Biopharma/Geoffrey Duyk
GD

Geoffrey Duyk

CEO

Grove Biopharma

Grove Biopharma Pipeline

DrugIndicationPhase
Bionic Biologics PlatformOncology, Neurodegeneration, Rare DiseasesPre-clinical
MYC/KRAS Degrader ProgramOncologyPre-clinical
KEAP1/NRF2 ProgramMyocardial InfarctionPre-clinical